Cargando…
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease
BACKGROUND AND AIMS: Matrix metalloproteinase-9 [MMP9] is implicated in the pathogenesis of ulcerative colitis [UC] via disruption of intestinal barrier integrity and function. A phase 2/3 combined trial was designed to examine the efficacy, safety, and pharmacokinetics of the anti-MMP9 antibody, an...
Autores principales: | Sandborn, William J, Bhandari, Bal R, Randall, Charles, Younes, Ziad H, Romanczyk, Tomasz, Xin, Yan, Wendt, Emily, Chai, Hao, McKevitt, Matt, Zhao, Sally, Sundy, John S, Keshav, Satish, Danese, Silvio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113706/ https://www.ncbi.nlm.nih.gov/pubmed/29767728 http://dx.doi.org/10.1093/ecco-jcc/jjy049 |
Ejemplares similares
-
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s Disease
por: Schreiber, Stefan, et al.
Publicado: (2018) -
A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma
por: Ooki, Akira, et al.
Publicado: (2022) -
Randomised clinical trial: a phase 1, dose‐ranging study of the anti‐matrix metalloproteinase‐9 monoclonal antibody GS‐5745 versus placebo for ulcerative colitis
por: Sandborn, W. J., et al.
Publicado: (2016) -
Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2021) -
Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis
por: Danese, Silvio, et al.
Publicado: (2022)